---
title: "Jiangsu Lianhuan Pharmaceutical Co.,Ltd. (600513.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600513.SH.md"
symbol: "600513.SH"
name: "Jiangsu Lianhuan Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:30:54.889Z"
locales:
  - [en](https://longbridge.com/en/quote/600513.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600513.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600513.SH.md)
---

# Jiangsu Lianhuan Pharmaceutical Co.,Ltd. (600513.SH)

## Company Overview

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprilite, danazol suppositories, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising ebastine, terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules. In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, drotaverine hydrochloride, felodipine, ebastine, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, hydrocortisone valerate, and bilastine.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.lhpharma.com](https://www.lhpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 130 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 28.10% |  |
| Net Profit YoY | -253.96% |  |
| P/B Ratio | 4.39 |  |
| Dividend Ratio | 0.45% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5622052488.53 |  |
| Revenue | 2899927282.17 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.52% | D |
| Profit Margin | -3.97% | D |
| Gross Margin | 26.52% | C |
| Revenue YoY | 28.10% | A |
| Net Profit YoY | -253.96% | E |
| Total Assets YoY | 14.71% | B |
| Net Assets YoY | -5.50% | D |
| Cash Flow Margin | 35.08% | D |
| OCF YoY | 28.10% | A |
| Turnover | 0.74 | B |
| Gearing Ratio | 59.39% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Lianhuan Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "28.10%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-253.96%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.39",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.45%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5622052488.53",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2899927282.17",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.52%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-3.97%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "26.52%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "28.10%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-253.96%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.71%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.50%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "35.08%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "28.10%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.74",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "59.39%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -48.24 | 202/215 | 80.54 | 47.32 | 36.97 |
| PB | 4.34 | 177/215 | 4.80 | 4.31 | 3.71 |
| PS (TTM) | 1.92 | 30/215 | 2.55 | 2.25 | 1.98 |
| Dividend Yield | 0.46% | 136/215 | 0.49% | 0.44% | 0.39% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600513.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600513.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600513.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600513.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**